Want to join the conversation?
$CTL expects 4Q15 operating revenues in the range of $4.40-4.45Bil and operating cash flow in the range of $1.72-1.77Bil, which are lower when compared to 3Q15, primarily driven by the retroactive recognition of CAF Phase 2 funds in 3Q15. Further, the company anticipates its adjusted diluted EPS to be in the range of $0.62-0.67 for 4Q15.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)